Rosetta Biosoftware has announced that CXR Biosciences Ltd., licensed the Rosetta Resolver® system to investigate mechanisms of drug toxicity.
CXR Biosciences plans to use the statistical analysis tools in the Resolver system to generate data to support its toxicological research using transcriptional profiling.
“We appreciate Rosetta Biosoftware's strong reputation for developing high-quality data management and statistical software for microarray analysis," said Tom Shepherd, Ph.D., Chief Executive Officer of CXR Biosciences.
“The Resolver system will provide us with a solid platform for determining the toxicological profiles of early-stage compounds, helping us to achieve one of CXR's strategic aims, which is to revolutionize the human risk assessment of drugs and chemicals.”
“At Rosetta Biosoftware, we developed the Resolver system to be a flexible and scalable framework to grow with a researcher's throughput needs,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.